Generic GLP-1 receptor agonists in India: an opportunity to close the cardiovascular evidence gap
The semaglutide patent expiry in India in March 2026 is expected to accelerate the entry of generic injectable formulations into a market with more than 100 million adults living with type 2 diabetes.1 However, an important evidence gap remains: no cardiovascular outcomes trial of a GLP-1 receptor agonist has specifically enrolled South Asians with sufficient representation for dedicated analysis.
Authors
- Ahmad Alam (ORCID: https://orcid.org/0009-0007-7533-8726)
- Mohammad Riashad Monjur (ORCID: https://orcid.org/0000-0003-1493-953X)
Institutions
- Camden and Campbelltown Hospitals (AU)
- Aligarh Muslim University (IN)
Publication Details
- Journal
- The Lancet Regional Health - Southeast Asia
- Published
- 2026-10-09
- DOI
- https://doi.org/10.1016/j.lansea.2026.100880
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00